A major clinical trial showed such promising results that the drug’s maker halted it early.

Sobi® and Apellis Pharmaceuticals, Inc. today announced positive one-year results from the phase 2 NOBLE study investigating systemic pegcetacoplan, a targeted C3 therapy, for the treatment of ...

“It is exciting to see that treatment with pegcetacoplan rapidly reduced disease ... Excessive C3c deposits are a marker of disease activity, which can lead to kidney inflammation, damage, and failure ...

The introduction of semaglutide as a treatment could revolutionize the management ... potentially slowing the progression of ...

Semaglutide, the same compound in obesity drug Wegovy, slashes risk of kidney failure and death for people with diabetes.

Slayman underwent surgery at Massachusetts General Hospital on March 16 and received a pig kidney with 69 genomic edits. He lived dialysis-free for 52 days following the historic procedure. Williams ...

Biogen said Wednesday it will acquire a California biotech that specializes in diseases of the immune system for $1.15 ...

Delays for medical care were severe enough to force one inmate at the prison to fake a suicide attempt to obtain treatment ...

Kidney transplant has been considered the best treatment option for chronic kidney disease patients who are on regular ...

The Lupus Research Alliance (LRA) is proud to announce that nine international researchers are the recipients of this year’s ...

Tygerberg Hospital treated 427 outpatients with Lupus Nephritis. With this condition, the kidneys become inflamed, leading to ...